Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.59 |
| ▸ | CTSS | P25774 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28778606 | 0.88 | CTSK (0.64) | CTSKCTSSCA2CAPN1CA1 | |
| SCHEMBL22960914 | 0.88 | CTSK (0.64) | CTSKCTSSCA2CAPN1CA1 | |
| SCHEMBL22960911 | 0.87 | CTSK (0.54) | CTSKCTSSCA2CAPN1CA1 | |
| SCHEMBL12056633 | 0.86 | CAPN1 (0.52) | CTSKCTSSCA2CAPN1CA1 | |
| SCHEMBL14160952 | 0.85 | CTSK (0.52) | CTSKCTSSCA2CAPN1CA1 | |
| SCHEMBL24097543 | 0.85 | CTSK (0.63) | CTSKCTSSCA2CAPN1CA1 | |
| SCHEMBL13934288 | 0.85 | CTSK (0.63) | CTSKCTSSCA2CAPN1CA1 | |
| SCHEMBL13934341 | 0.85 | CTSK (0.63) | CTSKCTSSCA2CAPN1CA1 | |
| SCHEMBL9788528 | 0.84 | CTSK (0.67) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL4470428 | 0.84 | CTSK (0.67) | CTSKCTSSCA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124190-A1 | METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12441723-B2 | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations | RIGEL PHARMACEUTICALS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12357623-B2 | Method for treating a disease or condition using a pyrazole compound or formulation thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240382470-A1 | Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory Virus | RIGEL PHARMACEUTICALS INC (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4399208-A1 | IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE-RELATED CONDITIONS ASSOCIATED WITH INFECTION BY A RESPIRATORY VIRUS | Rigel Pharmaceuticals, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20230399326-A1 | PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399326-A1 | PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| WO-2023038815-A1 | IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE-RELATED CONDITIONS ASSOCIATED WITH INFECTION BY A RESPIRATORY VIRUS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| US-20220306620-A1 | PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-09-29 | — | — | US | disclosed |
| US-20220288047-A1 | METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | US | disclosed |
| WO-2022187303-A1 | A METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20220249475-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | RIGEL PHARMACEUTICALS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| US-11370787-B2 | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations | RIGEL PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370787-B2 | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations | RIGEL PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| EP-4009974-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | Rigel Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20210061798-A1 | PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-04 | — | — | US | disclosed |
| WO-2021026451-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061798-A1 | PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS | IRAK1, IRAK3, IRAK2 | CTSK 2338/4885CTSS 4194/4885CA2 4663/4885 |
| US-20220306620-A1 | PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS | IRAK1, IRAK3, IRAK2 | CTSK 2338/4885CTSS 4194/4885CA2 4663/4885 |
| US-12441723-B2 | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations | IRAK1, IRAK3, IRAK2 | CTSK 2338/4885CTSS 4194/4885CA2 4663/4885 |
| US-12357623-B2 | Method for treating a disease or condition using a pyrazole compound or formulation thereof | MCL1, IL5, MALT1 | CTSK 740/4885CTSS 2011/4885CA2 4799/4885 |
| US-11370787-B2 | Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations | IRAK1, IRAK3, IRAK2 | CTSK 2338/4885CTSS 4194/4885CA2 4663/4885 |
| US-20220249475-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | IRAK1, IRAK3, IRAK2 | CTSK 328/4885CTSS 236/4885CA2 1376/4885 |
| US-20230399326-A1 | PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS | IRAK1, IRAK3, IRAK2 | CTSK 2338/4885CTSS 4194/4885CA2 4663/4885 |
| US-20240382470-A1 | Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory Virus | IRAK1, IRAK4, IRAK2 | CTSK 1564/4885CTSS 2030/4885CA2 1542/4885 |
| US-20220288047-A1 | METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF | MCL1, IL5, MALT1 | CTSK 740/4885CTSS 2011/4885CA2 4799/4885 |
| US-20260124190-A1 | METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF | IRAK2, IRAK3, IRAK1 | CTSK 2549/4885CTSS 3142/4885CA2 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.